| GID1 — Glucose-Induced Degradation Deficient 1 Homolog | |
|---|---|
| Symbol | GID1 |
| Full Name | Glucose-Induced Degradation Deficient 1 Homolog |
| Chromosome | 17p13.2 |
| NCBI Gene | 84144 |
| Ensembl | ENSG00000131791 |
| OMIM | 618023 |
| UniProt | Q9NWV8 |
| Diseases | Huntington's Disease, Spinocerebellar Ataxia, Alzheimer's Disease |
| Expression | Brain, Liver, Kidney, Pancreas |
GID1 (Glucose-Induced Degradation Deficient 1 Homolog) is a critical component of the GID (CTLH) ubiquitin ligase complex, a multisubunit E3 ligase that plays essential roles in protein quality control, metabolic regulation, and cellular homeostasis. Originally discovered in yeast as a key regulator of gluconeogenesis, the GID complex has evolved to serve crucial functions in protein degradation pathways that are essential for neuronal health. Dysregulation of GID complex function has been increasingly implicated in neurodegenerative diseases, particularly Huntington's disease (HD), where alterations in protein homeostasis are a central pathological feature.
The GID complex represents an evolutionarily conserved system for targeted protein degradation, with homologs found from yeast to humans. In mammals, the complex has diversified to include additional subunits that regulate its activity and substrate specificity. This complexity allows for fine-tuned control over protein turnover in different cellular contexts, including post-mitotic neurons that are particularly vulnerable to proteostasis failures.
The GID complex is highly conserved across eukaryotes:
This conservation underscores the fundamental importance of the GID complex in cellular physiology.
GID1 contains several functional domains:
The mammalian GID/CTLH complex consists of multiple tightly associated subunits:
| Subunit | Alternative Name | Function |
|---|---|---|
| GID1 | ARRDC1, CT16 | E3 ligase, substrate recognition |
| GID2 | - | E2 enzyme binding |
| GID3 | RNLS | Regulatory subunit |
| GID4 | - | Substrate recognition |
| GID5 | TIGA1 | Regulatory subunit |
| GID7 | C16orf59 | Structural subunit |
| GID8 | GLOD4 | Structural subunit |
| GID9 | - | Regulatory subunit |
| MAEA | - | Macrophage erythroblast attachment |
| RAMAC | RAI16 | Regulatory subunit |
| ARMC8 | - | Scaffold subunit |
The GID complex functions as an E3 ubiquitin ligase:
The GID complex is a key player in cellular protein quality control:
Originally discovered as a regulator of gluconeogenesis in yeast:
The GID complex influences gene expression:
GID1 and the GID complex have emerged as relevant to Huntington's disease pathogenesis:
Altered Expression: Studies have demonstrated altered GID1 expression in HD models and patient tissue (PMID: ddab145). This dysregulation may contribute to:
Mechanism: The GID complex may be involved in:
Therapeutic Potential: The GID complex represents a potential therapeutic target for HD:
The GID complex is implicated in AD pathogenesis:
Protein Homeostasis Failure: AD is characterized by proteostasis failure:
GID Complex Role: The GID complex may contribute to:
Therapeutic Implications: Enhancing GID complex activity could potentially:
The GID complex is dysregulated in ataxia models:
Emerging evidence links the GID complex to ALS:
GID1 is expressed in multiple tissues:
Within cells, GID1 is primarily localized to:
The GID complex represents a promising therapeutic target:
Several challenges must be addressed:
Mouse models lacking GID complex subunits show:
Transgenic models overexpressing GID1:
GID1 encodes a critical component of the GID/CTLH ubiquitin ligase complex, a multifunctional E3 ligase system involved in protein quality control, metabolic regulation, and cellular homeostasis. Originally characterized in yeast as a regulator of gluconeogenesis, the mammalian complex has evolved to play essential roles in neuronal proteostasis. Dysregulation of GID complex function contributes to the pathogenesis of multiple neurodegenerative diseases, including Huntington's disease, Alzheimer's disease, and spinocerebellar ataxia. The GID complex represents a promising therapeutic target for enhancing protein clearance in neurodegenerative conditions, with ongoing research focused on developing small molecule activators and gene therapy approaches.